Home
RayzeBio, Inc.

RayzeBio, Inc. Market Share Analysis for May 2026

Purposefully designing the discovery and development of innovative radiopharmaceuticals for solid tumors.

Health > Biotechnology and Pharmaceuticals

Domainrayzebio.com

Year Founded2020

Employees201 - 500

Annual Revenue--

RayzeBio, Inc.

RayzeBio, Inc. (including company regionals)

rayzebio.com

See more website traffic and engagement information

Total visits to RayzeBio, Inc.'s top domains

Understand RayzeBio, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

rayzebio.com6.4K

See more with Sales Intelligence

Avg. visit duration in RayzeBio, Inc.'s top domains

Analyze RayzeBio, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

rayzebio.com00:00:27

See more with Sales Intelligence

Avg. pageviews on RayzeBio, Inc.'s top domains

See how RayzeBio, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

rayzebio.com1.60

See more with Sales Intelligence

RayzeBio, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by RayzeBio, Inc.

These are the website technologies, by industry, used by RayzeBio, Inc. top domains

Content Management System (4)

WordPress

Mobile (2)

Meta Viewport

Widget (2)

Twemoji

Advertising (1)

PubMatic

More Technologies

6

See all

News & Signals from RayzeBio, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsRayzeBio, Inc. partnered with Philochem AG on Jun 1st '25.In June, the company, through its radiopharma subsidiary RayzeBio, partnered with Philochem to the tune of $350 million upfront and $1.35 billion in biobucks to work on prostate cancer.

NewsKarmann left RayzeBio, Inc. on Dec 4th '23.Dr. Karmann joins from RayzeBio, recently acquired by Bristol Myers Squibb, where she led the development of early-stage assets and provided strategic and clinical leadership for the GPC3 and CA9 programs, in addition to leading global compassionate use programs.

NewsRayzeBio, Inc. acquires Karunatx for $14B.The big drug maker's deal to acquire RayzeBio came just days after the company said it would buy Karuna Therapeutics for $14 billion.